- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05857293
PDA Stent in Neonates With PDA Dependent Pulmonary Circulation
May 10, 2023 updated by: Somia Sabry Mahmoud, Sohag University
Outcomes for Patent Ductus Arteriosus Stenting in Neonates With Duct-Dependent Pulmonary Circulation: A Prospective Study at Sohag University Hospital
After echocardiography confirmation of PDA dependent pulmonary circulation in cyanotic neonates, catheter-guided PDA stent implantation will be done.
Under general Anasthesia and after discontinuation of prostaglandin 4-6 hours before procedure, obtain vascular access and unfractionated heparin is given, then duct is accessed via a cut pig-tail or Judkins right [JR] catheter, and is crossed by PTCA wire to be carefully placed in the left or right branch pulmonary arteries, choose proper stent diameter and length, place the stent and confirm it's position, NICU admission for the neonate with heparin infusion for 24-48 hrs and acetylsalicylic acid is given then follow up the patient by pulse oximeter and echocardiography
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Somaia S Mahmoud, Master
- Phone Number: 201019052097
- Email: somaia_sabry922@yahoo.com
Study Locations
-
-
-
Sohag, Egypt
- Recruiting
- Sohag University
-
Contact:
- Somaia S Mahmoud, Master
- Phone Number: 201019052097
- Email: somaia_sabry922@yahoo.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Neonates and young infants with duct dependent pulmonary circulation
Exclusion Criteria:
- Untreated sepsis.
- Coagulopathy.
- PDA dependent systemic circulation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cyanotic neonate
Cyanotic neonates with PDA dependent pulmonary circulation will be treated with catheter guided PDA stent implantation to keep duct patency and improve oxygen saturation
|
PDA stent is the primary treatment for patients with duct-dependent pulmonary circulation.
It serves as a temporary bridge for later surgical repair by keeping the duct patent to improve oxygen saturation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Oxygen saturation
Time Frame: Change in oxygen saturation within 24 hours
|
Using pulse oximeter to assess oxygen saturation
|
Change in oxygen saturation within 24 hours
|
|
Evaluation of duct patency
Time Frame: 1 month
|
Using echocardiography assess flow through the duct
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Somaia S Mahmoud, Master, Sohag University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2023
Primary Completion (Anticipated)
March 31, 2025
Study Completion (Anticipated)
March 31, 2025
Study Registration Dates
First Submitted
May 2, 2023
First Submitted That Met QC Criteria
May 10, 2023
First Posted (Actual)
May 12, 2023
Study Record Updates
Last Update Posted (Actual)
May 12, 2023
Last Update Submitted That Met QC Criteria
May 10, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Soh-Med-23-04-03MD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonatal Cyanosis Due to PDA Dependent Pulmonary Circulation
-
University of Alabama at BirminghamRecruitingBronchopulmonary Dysplasia | Ventilation Perfusion Mismatch | Ventilator Lung; Newborn | Extreme Prematurity | Pulmonary Hypertension Due to Lung Diseases and HypoxiaUnited States
-
Suneet AgarwalRecruitingDyskeratosis Congenita | Hoyeraal Hreidarsson Syndrome | Revesz Syndrome | Telomere Biology Disorders | Telomere Biology Disorders With Bone Marrow Failure | Interstitial Lung Disease Due to Systemic Disease (Telomere Biology Disorder) | Pulmonary Fibrosis, Familial (Telomere Biology Disorder)United States
-
Healing Hope InternationalEnrolling by invitationQuality of Life | Vasomotor Symptoms | Menopause | Cell Therapy | Hormone Disturbance | Premature Ovarian Failure | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men | Diminished Ovarian Reserve | Perimenopause | Vasomotor Symptoms Associated With Menopause | Premature Ovarian Failure... and other conditionsMexico
-
RTI InternationalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsEnrolling by invitationPrimary Hyperoxaluria Type 3 | Diabetes Mellitus | Hemophilia A | Hemophilia B | Hereditary Fructose Intolerance | Cystic Fibrosis | Factor VII Deficiency | Phenylketonurias | Sickle Cell Disease | Dravet Syndrome | Duchenne Muscular Dystrophy | Prader-Willi Syndrome | Fragile X Syndrome | Chronic Granulomatous Disease and other conditionsUnited States
Clinical Trials on Catheter-guided PDA stent implantation
-
Shanghai Bluesail Boyuan Medical Technology Co....Not yet recruitingCoronary Artery Disease | Coronary Artery Calcification | Severe Coronary Artery DiseaseChina
-
Shanghai Zhongshan HospitalUnknownPercutaneous Coronary Intervention | Acute Myocardial InfarctionChina
-
Shenyang Northern HospitalChinese Academy of Medical Sciences, Fuwai HospitalNot yet recruitingCoronary Artery Disease (CAD) | Acute Coronary Syndrome (ACS) | High Bleeding Risk(HBR)China
-
Second Affiliated Hospital, School of Medicine,...The First Affiliated Hospital of Nanchang University; Seoul St. Mary's Hospital and other collaboratorsRecruitingCoronary Artery DiseaseKorea, Republic of, China
-
Yonsei UniversityCompleted
-
Terumo Europe N.V.Active, not recruitingSuperficial Femoral Artery Disease | Popliteal Artery DiseaseSpain, Belgium, Germany, France, Netherlands
-
Samsung Medical CenterCompletedTumor Appearance of Biliary System ObstructionKorea, Republic of
-
Ruijin HospitalShanghai Tong Ren Hospital; Shanghai Pulmonary Hospital, Shanghai, China; Ruijin...UnknownAirway Disease | Fistula Bronchial | Fistula, GastricChina
-
Montreal Heart InstituteCompletedST-elevation Myocardial InfarctionFrance, Canada
-
Southeast University, ChinaScience and Technology Department of Jiangsu ProvinceCompletedCoronary Artery Disease | Coronary Artery Disease ProgressionChina